Vaccine maker Modern could soon be on the market with a vaccine to be used against the omicron variant of the coronavirus.
This was confirmed by the head of the pharmaceutical company Stefan Bansel, reports Reuters.
Moderna hopes to begin clinical trials of the rapidly spreading omicron vaccine early next year but is currently focusing on an additional dose of the current mRNA-1273 vaccine.
It will take them about two weeks
“Only small adjustments are required for omicron. “I do not expect any problems,” Bansel said in an interview with the Swiss newspaper TagesAnzeiger published on Tuesday.
He added that this could happen in the next “week to two weeks”.
“It will be several months before we can produce 500 million doses after regulatory approval. “But our capacity is much higher today than it was a year ago.”
The company has produced between 700 and 800 million doses of Covid-19 vaccines this year, and is expected to produce more in 2022, increasing production from 100 million doses per month to 150 million.
They are also developing other vaccines
“We are developing a number of new vaccines, such as against the flu or a virus that causes a respiratory disease that is fatal in the elderly and young children,” Bansel said.
“We can combine these three mRNA vaccines in one dose and suggest to governments to provide reserves for a certain amount for a few years, and then invest in production capacity in that country,” he added.